How prostate cancer drugs affect a new medicine
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how a new medicine called fezolinetant is processed by the body when taken alongside common prostate cancer hormone treatments. It is an early-phase trial that helps researchers understand if there are any drug interactions, which could be important for future treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer that is confirmed by biopsy or other cell sample.
- You need to be taking a hormone therapy like enzalutamide, apalutamide, or bicalutamide for at least 3 months before starting.
- You must also be receiving a GnRH agonist or antagonist (types of hormone therapy) for at least 3 months.
- Your cancer should not be causing major symptoms; you should be able to care for yourself (ECOG score 0 or 1).
- You cannot have had chemotherapy, immunotherapy, or prostate cancer surgery in the last 3 months.
- Your body mass index (BMI) must be between 18.5 and 30, and you must weigh at least 110 pounds (50 kg).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether fezolinetant can reduce hot flushes in men receiving hormone therapy (ADT) for prostate cancer. If you have bothersome hot flushes, this treatment may help lessen them.
This study looks at how levels of common prostate cancer hormone treatments (abiraterone, apalutamide, darolutamide, or enzalutamide) stay in your blood over time. By checking drug levels, doctors hope to personalize dosing to make treatment safer and more effective.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.